Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Cempra: Currently Breaking Out Of Consolidation

Published 02/23/2015, 04:04 AM
Updated 07/09/2023, 06:32 AM

Cempra (CEMP) specializes in treating critical bacterial infectious diseases. It has a number of Phase 3 clinical candidates specifically targeted to kill drug-resistant bacterial infections in the hospital and the community. As widespread use of general antibiotics continues, we are seeing an increase of "super-germs" or infections not responding to existing medications. One of CEMP's products Solithromycin is in Phase 3 clinical development for community acquired bacterial pneumonia which kills in excess of 25,000 people per year (Wikipedia). CEMP does a lot of very complicated developmental work which I will not get into here, but what interests me is the chart. Let's take a look:

CEMP Daily

Looking at the chart we can see that CEMP created its first base between October and December of 2014 before staging a massive run up that essentially doubled its share price. Since Jan 2015 this stock has been working on its second base and currently appears to be breaking out of consolidation. If you look at the bollinger bands you can see the bottom band is relatively flat while the top band has started to flare open creating space for price to move upwards. Moving down to the MACD, we can see that the black line has crossed the red line creating a buy signal and the histogram is stair-stepping up - both bullish signs. Finally, looking at the full stochastic, we see that this chart is not yet overbought, but when it gets there it can stay there for quite some time.

Biotech stocks are not for the faint of heart as they are ruled by trial results, FDA approvals and are notorious for doing secondary offerings when you least expect them - but when you choose a good stock with a viable product and trade it technically it can earn handsome profits for your portfolio. As the bid/ask spreads are so wide on CEMP I would trade it in common vs. options.

CEMP is scheduled to report earnings on February 25, 2015 after market close. As always please use proper sizing for your portfolio and engage in the use of stops to help contain losses.

Full Disclosure: I own CEMP common

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.